Department of Biochemistry, Laboratory of Biochemical Pharmacodynamy, Félix Houphouet-Boigny University,
Abidjan, Ivory Coast
Guest Editors
Konan Kouassi
Department of Biochemistry, Laboratory of Biochemical Pharmacodynamy, Félix Houphouët-Boigny University,
Abidjan, Ivory Coast
Rita Bouagnon
Department of Biochemistry, Laboratory of Biochemical Pharmacodynamy, Félix Houphouët-Boigny University,
Abidjan, Ivory Coast
Alain Dit Philippe Bidie
Department of Biochemistry, Laboratory of Biochemical Pharmacodynamy, Félix Houphouët-Boigny University,
Abidjan, Ivory Coast
Allico Joseph Djaman
Department of Medical and Fundamental Biochemistry, Pasteur Institute,
Abidjan, Ivory Coast
Jean David N’Guessan
Department of Biochemistry, Laboratory of Biochemical Pharmacodynamy, Félix Houphouët-Boigny University,
Abidjan, Ivory Coast
Houphouet Felix Yapi
Department of Biochemistry, Laboratory of Biochemical Pharmacodynamy, Félix Houphouët-Boigny University,
Abidjan, Ivory Coast
Introduction
Doxorubicin (dox) is one of the most effective antitumor antibiotics belonging to the class of anthracyclines. However, its use is limited by a high incidence of irreversible myocardial damage and dilatation.
Several approaches may be taken to decrease the risk of dox-induced cardiotoxicity while maintaining its efficacy. These include altered schedules of drug administration, modifications of the anthracycline molecule, adjunctive treatment with beta-adrenergic blockers, angiotensin-converting enzyme inhibitors (ACEi), dexrazoxane, and probucol. None of these have been entirely successful. A new drug to prevent or treat Dox-induced cardiotoxicity is therefore needed.
The therapeutic actions of most medicinal plants are related to their antioxidant properties which, in turn, could be ascribed to their antioxidant phytochemicals. The cardioprotective effect of various medicinal plants and plant products have been documented. Sustainable agents from natural sources could serve as viable alternatives to currently available synthetic drugs in the management of cardiovascular-related disorders. This is especially important owing to the toxic side effects of most synthetic drugs and their high costs which make them not readily accessible to many patients in developing countries like Cote d’Ivoire.